Dopamine: 50 years in perspective

Trends in Neurosciences

Volumn 30, Issue 5, 2007, Pages 188-193

  Iversen, Susan D ^a   Iversen, Leslie L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; CARBIDOPA; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PHOSPHOPROTEIN DARPP 32;

ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DRUG POTENTIATION; HUMAN; IN VIVO STUDY; NEUROPHYSIOLOGY; NEUROPSYCHOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; DOPAMINE; HUMANS; NEURONS;

EID: 34247543124     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2007.03.002     Document Type: Review

References (86)

1. In: Vane J.R., et al. (Ed). Ciba Foundation Symposium on 'Adrenergic Mechanisms' (1960), J&A Churchill
2. Kebabian J.W., et al. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the 'dopamine receptor'. Proc. Natl. Acad. Sci. U. S. A. 69 (1972) 2145-2149
3. Miller R.J., et al. The actions of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3′,5′-monophosphate production in rat neostriatum and limbic forebrain. Mol. Pharmacol. 10 (1974) 759-766
4. Creese I., et al. Dopamine receptors and average clinical doses. Science 194 (1976) 545-546
5. Seeman P., et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 4376-4380
6. Werkman T.R., et al. Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. CNS Neurol. Disord. Drug Targets 5 (2006) 3-23
7. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr. Opin. Pharmacol. 4 (2004) 53-57
8. Burris K.D., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
9. Greengard P. The neurobiology of slow synaptic transmission. Science 294 (2001) 1024-1030
10. Cheramy A., et al. Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Amino Acids 14 (1988) 63-68
11. Cheramy A., et al. Dendritic release of dopamine in the substantia nigra. Nature 289 (1981) 537-542
12. Marsden C.A., et al. In vivo voltammetry - present electrodes and methods. Neuroscience 25 (1988) 389-400
13. Zetterström T., et al. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after amphetamine. J. Neurochem. 41 (1983) 1769-1773
14. Sedvall G., and Farde L. Chemical brain anatomy in schizophrenia. Lancet 346 (1995) 743-749
15. Volkow N.D., et al. PET evaluation of the dopamine system of the human brain. J. Nucl. Med. 37 (1996) 1242-1256
16. Volkow N.D., et al. The addicted human brain: insights from imaging studies. J. Clin. Invest. 111 (2003) 1444-1451
17. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 367 Suppl. (1971) 1-48
18. Moore R.Y., and Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu. Rev. Neurosci. 1 (1978) 129-169
19. Uretsky N.J., and Iversen L.L. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J. Neurochem. 17 (1970) 269-278
20. Ungerstedt U. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol. Ther. B 2 (1976) 37-40
21. Barnes T.D., et al. Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature 437 (2005) 1158-1161
22. Gerfen C.R., et al. The neostriatal mosaic. II. Patch and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 7 (1987) 3915-3934
23. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 26 (2003) 317-330
24. Alexander G.E., et al. Basal ganglia-thalamocortical circuits: parallel substrates for motor, occulomotor, 'prefrontal' and 'limbic' functions. In: Uylings H.B.M., et al. (Ed). The Prefrontal Cortex: its Structure, Function and Pathology (1990), Elsevier 119-146
25. Björklund A., et al. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199 (1980) 307-333
26. Dunnett S.B., et al. Cell therapy in Parkinson's disease - stop or go?. Nat. Rev. Neurosci. 2 (2001) 365-369
27. Döbrössy M.D., and Dunnett S.B. The influence of environment and experience on neural grafts. Nat. Rev. Neurosci. 2 (2001) 871-879
28. Heimer L., et al. The accumbens: beyond the core-shell dichotomy. J. Neuropsychiatry. Clin. Neurosci. 9 (1997) 354-381
29. Mogenson G.J., et al. From motivation to action: functional interaction between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
30. Dickinson A. In: Mackintosh N.J. (Ed). Animal Learning and Cognition (1994), Academic Press 45-79
31. Dickinson A., and Balleine B. Motivational control of goal-directed action. Anim. Learn. Behav. 22 (1994) 1-18
32. Balleine B., and Dickinson A. Instrumental performance following reinforcer devaluation dependence upon incentive learning. Q. J. Exp. Psychol. 43 (1991) 279-296
33. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward? Hedonic impact, reward learning or incentive salience?. Brain Res. Rev. 28 (1998) 309-369
34. Olds J., and Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J. Comp. Physiol. Psychol. 47 (1954) 419-427
35. Crow T.J. Catecholamine-containing neurons and electrical self stimulation: a review of some data. Psychol. Med. 2 (1972) 414-421
36. Wise R.A. Catecholamine theories of reward: a critical review. Brain Res. 152 (1978) 215-247
37. Robbins T.W., and Everitt B.J. Neurobehavioural mechanisms of reward and motivation. Curr. Opin. Neurobiol. 6 (1996) 228-236
38. Cardinal R.N., et al. Emotion and motivation: the role of the amygdala, ventral striatum and prefrontal cortex. Neurosci. Biobehav. Rev. 26 (2002) 321-352
39. Salamone J.D., and Corres M. Motivational views of reinforcement: implications for understanding the behavioural functions of nucleus accumbens dopamine. Behav. Brain Res. 137 (2002) 3-25
40. Kapur S. How antipsychotics become anti-'psychotic' - from dopamine to salience to psychosis. Trends Pharmacol. Sci. 25 (2004) 402-406
41. Kelley A.E. Ventral striatum control of appetitive motivation in ingestive behaviour and reward-related learning. Neurosci. Biobehav. Rev. 27 (2004) 765-776
42. Kelley A.E., et al. Response-reinforcement learning is dependent on NMDA receptor activation in the nucleus accumbens core. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12174-12179
43. Corbit L.H., et al. The role of the nucleus accumbens in instrumental conditioning: evidence of a functional dissociation between accumbens core and shell. J. Neurosci. 21 (2001) 3251-3260
44. Reynolds S.M., and Berridge K.C. Positive and negative motivation in nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eating, taste 'liking/dislike' reactions, place preference/avoidance and fear. J. Neurosci. 22 (2002) 7308-7320
45. Salamone J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61 (2004) 117-133
46. Parkinson J.A., et al. Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive Pavlovian approach behaviour and the potentiation of conditioned reinforcement and locomotor activity by d-amphetamine. J. Neurosci. 19 (1999) 2401-2411
47. Schultz W. Multiple reward signals in the brain. Nat. Rev. Neurosci. 1 (2000) 199-207
48. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
49. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
50. Waelti P., et al. Dopamine responses comply with basic assumptions of formal learning theory. Nature 412 (2001) 43-48
51. Zaborszky L., et al. Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study. Neuroscience 14 (1985) 427-453
52. Usuda I., et al. Efferent projections of the nucleus accumbens in the rat with special reference to subdivision of the nucleus: biotinylated dextran amine study. Brain Res. 797 (1998) 73-93
53. Voorn P., et al. The compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine and calcium-binding protein. J. Comp. Neurol. 289 (1989) 189-201
54. Voorn P., et al. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 27 (2004) 468-474
55. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav. Brain Res. 137 (2002) 75-114
56. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18 (1993) 247-291
57. Everitt B.J., et al. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N. Y. Acad Sci. 877 (1999) 412-438
58. Rosenkranz J.A., and Grace A.A. Dopamine-mediated modulation of odour-evoked amygdala potentials during Pavlovian conditioning. Nature 417 (2002) 282-287
59. Sawaguchi T., and Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251 (1991) 947-950
60. Williams G.V., and Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376 (1995) 572-575
61. Wang M., et al. Selective D2 receptor actions on the functioning circuitry of working memory. Science 303 (2004) 853-856
62. Desimone R. Is dopamine a missing link?. Nature 376 (1995) 549-550
63. Goldman-Rakic P.S. Dopamine mediated mechanisms of the prefrontal cortex. Semin. Neurosci. 4 (1992) 149-159
64. Tunbridge E.M., et al. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60 (2006) 141-151
65. Ehringer H., and Horynkiewicz O. Verteilung von noradrenalin und dopamine (3-hydroxtyramin) im gehirn des menschen und ihr verhalten bei erkankungen des extrapyamidalen systems. Klin. Wschr. 38 (1960) 1236-1239
66. Birkmayer W., and Hornykiewicz O. Der l-3,4-dioxyphenylalanin (l-DOPA) - effect bei der Parkinson-akinese. Wien. Klin. Wschr. 73 (1961) 787-788
67. Barbeau A., et al. Les catecholamines dans la maladie de Parkinson. Monoamines et Système Nerveux Central (1962), Georg et C, Geneva pp. 247-262
68. Cotzias G.C. L-DOPA for Parkinsonism. N. Engl. J. Med. 278 (1968) 630
69. Thomson F., et al. Parkinson's disease: treatment. Pharm. J. 267 (2001) 600-613
70. Gosal D., et al. Parkinson's disease: the genetics of a heterogeneous disorder. Eur. J. Neurol. 13 (2006) 616-627
71. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
72. Van Rossum J.M. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160 (1966) 492-494
73. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. (Kbh.) 20 (1963) 140-144
74. Janssen P.A.G., et al. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I. Neuroleptic activity spectra for rats. Arzn. Forsch. 15 (1965) 104-117
75. Moore K.E. The actions of amphetamine on neurotransmitters: a brief review. Biol. Psychiatry 12 (1977) 451-462
76. Randrup A., and Munkvad I. Biochemical, anatomical and psychological investigations of stereotyped behaviour induced by amphetamines. In: Costa E., and Garratini S. (Eds). Amphetamine and Related Compounds (1970), Raven Press 695-713
77. Creese I., and Iversen S.D. The role of forebrain dopamine systems in amphetamine induced stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Psychopharmacology (Berl.) 39 (1974) 345-357
78. Kelly P.H., et al. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94 (1975) 507-522
79. Angrist B., and Sudilovsky A. Central nervous system stimulants: historical aspects and clinical effects. In: Iversen L.L., et al. (Ed). Handbook of Psychopharmacology Vol. 11 (1978), Plenum Press 99-165
80. Matthysse S. Antipsychotic drug actions: a clue to the pathology of schizophrenia?. Fed. Proc. 32 (1973) 200-205
81. Snyder S.H., et al. Drugs, neurotransmitters and schizophrenia. Science 184 (1974) 1243-1245
82. Iversen L.L. Speed, Ecstasy, Ritalin: the Science of Amphetamines (2006), Oxford University Press
83. Abi-Dargham A., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8104-8109
84. High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3513-3518
85. Volkow N.D., et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry 161 (2004) 1173-1180
86. Bobb A.J., et al. Molecular genetic studies of attention deficit hyperactivity disorder 1991-2004. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 132 (2005) 109-125